NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Dose-Escalation Results from Full Phase 1 NEO212-01 Readout for Dosing and Toxicity

Core Insights - NeOnc Technologies Holdings, Inc. will host an investor conference call and webcast on March 4, 2026, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time to discuss initial data from the Phase 1 dose-escalation portion of the NEO212-01 clinical trial [1][2] Company Overview - NeOnc is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) cancers, utilizing its proprietary NEO™ drug development platform [3] - The company has a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038, including NEO100™ and NEO212™, which are currently in Phase II human clinical trials under FDA Fast-Track and Investigational New Drug (IND) status [3] Clinical Trial Update - The upcoming conference call will provide updates on the Phase 1 dose-escalation portion of the NEO212-01 clinical trial, including safety and toxicity data, dose-escalation observations, pharmacokinetic findings, and planned regulatory next steps [2][3]